2024-03-06T04:30:27.290Z

OCEANiC

OCEANiC
Lung cancer

A study on the effect of Osimertinib, with or without Adjuvant Chemotherapy, Guided by Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients with Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Following Complete Surgical Resection

A study on the effect of Osimertinib, with or without Adjuvant Chemotherapy, Guided by Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients with Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Following Complete Surgical Resection

Trial overview

Topic

Lung cancer

Trial registration

Number: ACTRN12623000552684

Study details

The purpose of this study is to investigate whether we can use co-mutation NGS profiling (looks for gene changes in your cancer tissue) and circulating tumour (ct) DNA (looks for fragments of the tumour moving through the blood stream. These fragments are known as circulating tumour DNA (ctDNA) and carry genetic information) to determine which patients with EGFR mutant non-small-cell lung cancer can safely avoid chemotherapy.

Further information

Click here for further information

Location

GenesisCare North Shore – PI: Prof. Nick Pavlakis

 

GenesisCare North Shore – PI: Prof. Nick Pavlakis   :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.